Literature DB >> 3047930

High incidence of monoclonal immunoglobulins in patients after liver or heart transplantation.

D Peest1, B Schaper, B Nashan, K Wonigeit, E Raude, R Pichlmayr, A Haverich, H Deicher.   

Abstract

Sera from 56 recipients of liver or heart transplants were investigated for monoclonal immunoglobulins (mIg) by immunofixation electrophoresis (IFE) at different times during 4 years after transplantation. Transient, changing, or stable mIgs were found in 18 patients. A significantly increased mIg incidence was observed in heart Tx patients, patients over 40 years of age, and those receiving azathioprine or antithymocyte globulin in addition to prednisolone and cyclosporine as immunosuppressive treatment. No correlations could be found between the presence of mIg and the number of rejection episodes or intercurrent infections. Such serum mIg represent monoclones of at least 1 x 10(9) cells of B lymphocyte lineage that apparently proliferate without adequate suppressive control. Since immunosuppressed allograft recipients are at risk of developing B cell lymphomas, such monoclones may be regarded as prelymphomas necessitating a careful follow-up in these patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3047930     DOI: 10.1097/00007890-198809000-00011

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder.

Authors:  E A Engels; J Preiksaitis; A Zingone; O Landgren
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

2.  Oligo-monoclonal immunoglobulins frequently develop during concurrent cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections in patients after renal transplantation.

Authors:  E Drouet; C Chapuis-Cellier; S Bosshard; C Verniol; A Niveleau; J L Touraine; J L Garnier
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

3.  Potentiation of in vitro synthesis of human IgE by cyclosporin A (CsA).

Authors:  D J Wheeler; A Robins; D I Pritchard; R V Bundick; F Shakib
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

4.  Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients.

Authors:  Eric A Engels; Barbara Savoldo; Ruth M Pfeiffer; Rene Costello; Adriana Zingone; Helen E Heslop; Ola Landgren
Journal:  Transplantation       Date:  2013-02-15       Impact factor: 4.939

5.  Effects of cyclosporine and rapamycin on immunoglobulin production by preactivated human B cells.

Authors:  H S Kim; J Raskova; D Degiannis; K Raska
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

6.  Plasma cell neoplasms in US solid organ transplant recipients.

Authors:  Eric A Engels; Christina A Clarke; Ruth M Pfeiffer; Charles F Lynch; Dennis D Weisenburger; Todd M Gibson; Ola Landgren; Lindsay M Morton
Journal:  Am J Transplant       Date:  2013-05-01       Impact factor: 9.369

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.